Empagliflozin reduces cardiovascular mortality in Type 2 DM beyond glycaemic control. The mechanism responsible for its cardioprotective effect, distinct from SGLT2 inhibition, is proposed to be:

• A Reduction of SBP through glucosuria-mediated caloric loss
• B Increase in HDL cholesterol and reduction in LDL
• C Activation of AMPK in myocardium, stimulating mitochondrial biogenesis
• D Direct inhibition of sodium-hydrogen exchanger (NHE-1) in myocardial cells, reducing intracellular calcium overload ✓

Explanation

Beyond glycosuria, empagliflozin's direct cardiac protection is increasingly attributed to inhibition of the sodium-hydrogen exchanger isoform 1 (NHE-1) in cardiomyocytes. SGLT2 inhibitors share structural resemblance with NHE inhibitors, and by inhibiting NHE-1, they reduce intracellular Na+ accumulation, which in turn improves Na+/Ca2+ exchanger efficiency, reducing calcium overload, diastolic stiffness, and cardiomyocyte injury. Additionally, they promote ketone body utilization as a cardiac substrate ('thrifty substrate hypothesis') and reduce cardiac preload and afterload via natriuresis/diuresis. The blood pressure and lipid effects are modest and not the primary cardioprotective mechanism.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.